Potentially harmful medication use and the associated factors among pregnant women visiting antenatal care clinics in Mbarara Regional Referral Hospital, Southwestern Uganda
Background: Pregnancy management using medications has been challenging for both healthcare providers and pregnant women, given the fear of teratogenicity effects and the potential for fetal harm. In the developing world, poor health-seeking behavior of patients, delayed initiation of Antenatal Care (ANC), and low level of educational status of mothers could contribute to the issue of drug safety in pregnancy.
Aim: To determine the prevalence and factors associated with potentially harmful medication use in pregnancy.
Methods: A cross-sectional study was conducted from April 1st to June 6th, 2021, including 209 pregnant women on ANC follow-up at a referral hospital in southwestern Uganda. The simple random sampling technique was employed to select study participants. Interviewer-administered questionnaires were used to collect the history of medication use since conception and then the participant’s antenatal care card was reviewed to determine prescribed drug regimens and their indications. Statistical Package for Social sciences (SPSS) version 23.0 was used for analysis.
Results: Out of the 1,422 medications used by 209 women, 665 (42.2%) were category C, and 182 (11.5%) were category A. A total of 92 (44.0%) pregnant women used at least one potentially harmful medication during the current pregnancy. Having more than average monthly income (AOR = 2.32 [1.04, 5.14 at 95% CI]), having a chronic disease (AOR = 3.24 [1.17, 8.97 at 95% C.I]), using 7 and more medications (AOR = 9.12 [4.11, 20.24 at 95% C.I]), use of herbal medicines (AOR = 4.50 [2.10, 9.87 at 95% CI]) were shown to be risk factors.
Conclusion: The proportion of pregnant women that used at least one potentially harmful medication is higher than in previous studies. Having comorbidities and taking more medications increase the risk of receiving a potentially harmful medication during pregnancy.
Relevance to patients: This study identified the gaps in the use of medicines during pregnancy which will enable the development and implementation of protocols for optimizing prescribing practices in pregnant women by focusing on the safety of the fetus.
[1] Wacha J, Szijártó A. Probiotics and Pregnancy. Orv Hetil 2011;152:420-6.
[2] Belay M, Kahaliw W, Ergetie Z. Assessment of Drug Utilization Pattern During Pregnancy in Adama Riferral Hospital, Oromia Region, Ethiopia. Int J Pharm Sci Res 2013;4:1905.
[3] Garzon S, Cacciato PM, Certelli C, Salvaggio C, Magliarditi M, Rizzo G. Iron Deficiency Anemia in Pregnancy: Novel Approaches for an Old Problem. Oman Med J 2020;35:e166.
[4] Racicot K, Kwon JY, Aldo P, Silasi M, Mor G. Understanding the Complexity of the Immune System During Pregnancy. Am J Reprod Immunol 2014;72:107-16.
[5] Gawde S, Bhide S, Patel T, Chauhan A, Mayadeo N, Sawardekar S. Drug Prescription Pattern in Pregnant Women Attending Antenatal Out Patient Department of a Tertiary Care Hospital. Br J Pharm Res Int 2013;3:1-12.
[6] Gebreegziabher TL, Berhe DF, Gutema GB, Kabtyimer BN. Drug Utilization Pattern and Potential Teratogenesity Risk among Pregnant Women; The Case of Ayder Referral Hospital, Tigray-Ethiopia. Int J Pharm Sci Res 2012;3:1371-8.
[7] US FDA. Pregnancy and Lactation Labeling (drugs) Final Rule. Maryland, United States: US Food and Drug Administration; 2021.
[8] Geresu GD, Sondesa DT, Yadesa TM, Mtewa AG, Abebe BA. Drug Use Evaluation in Pregnant WomenAttending Antenatal Care in Shashemene Referral Hospital, Oromia Regional State, Ethiopia. SAGE Open Med 2020;8:1-7.
[9] Mohammed MA, Ahmed JH, Bushra AW, Aljadhey HS. Medications Use among Pregnant Women in Ethiopia: A Cross Sectional Study. J Appl Pharm Sci 2013;3:116.
[10] Mengesha EW. Drug Use and its Associated Factors among Pregnant Women in Bahir Dar City Administration, Northwest Ethiopia. Int J Sex Reprod Health Care 2019;2:21-6.
[11] UCG. Uganda Clinical Guidelines, Ministry of Health; 2016.
[12] Sema FD, Addis DG, Melese EA, Nassa DD, Kifle ZD. Prevalence and Associated Factors of Self-Medication among Pregnant Women on Antenatal Care Follow-up at University of Gondar Comprehensive Specialized Hospital in Gondar, Northwest Ethiopia: A Cross-Sectional Study. Int J Reprod Med 2020;2020:2936862.
[13] Bentley DP. Iron Metabolism and Anaemia in Pregnancy. Clin Haematol 1985;14:613-28.
[14] Yip L, McCluskey J, Sinclair R. Immunological Aspects of Pregnancy. Clin Dermatol 2006;24:84-7.
[15] Al-Hamimi JZ, Al Balushi KA. Patterns of Prescription Drugs Use among Pregnant Women at Sultan Qaboos University Hospital and Sultan Qaboos University Hospital Family and Community Medicine Clinic, Oman. J Pharm Bioallied Sci 2016;8:309-13.
[16] Molla F, Assen A, Abrha S, Masresha B, Gashaw A, Wondimu A, et al. Prescription Drug Use during Pregnancy in Southern Tigray Region, North Ethiopia. BMC Pregnancy Childbirth 2017;17:170.
[17] Haas DM, Marsh DJ, Dang DT, Parker CB, Wing DA, Simhan HN, et al. Prescription and Other Medication Use in Pregnancy. Obstet Gynecol 2018;131:789-98.
[18] Marwa KJ, Njalika A, Ruganuza D, Katabalo D, Kamugisha E. Self-Medication among Pregnant Women Attending Antenatal Clinic at Makongoro Health Centre in Mwanza, Tanzania: A Challenge to Health Systems. BMC Pregnancy Childbirth 2018;18:16.
[19] Wakjira G, Boru B, Labata B. Prevalence of SelfMedication and its Associated Factors among Pregnant Women Attending Antenatal Care at Nekemte Referral Hospital, Oromia Regional State, West Ethiopia. J Bioanal Biomed 2019;11:160-5.
[20] Adane F, Seyoum G, Alamneh YM. Non-Prescribed Drug Use and Predictors among Pregnant Women in Ethiopia: Systematic Review and Meta-Analysis. J Matern Fetal Neonatal Med 2020;35:4273-84.
[21] Gebremedhin GL, Gomathi P. Assessment of Drug Use and Effect in Pregnant Women Attending Antenatal Care in Hospitals Of Mekelle, Tigray, Ethiopia. J Drug Deliv Ther 2014;4:75-82.
[22] Kebede B, Gedif T, Getachew A. Assessment of Drug Use among Pregnant Women in Addis Ababa, Ethiopia. Pharmacoepidemiol Drug Saf 2009;18:462-8.
[23] Walsh JW, Hasler WL, Nugent CE, Owyang C. Progesterone and Estrogen are Potential Mediators of Gastric SlowWave Dysrhythmias in Nausea of Pregnancy. Am J Physiol 1996;270:G506-14.
[24] Bayisa B, Tatiparthi R, Mulisa E. Use of Herbal Medicine among Pregnant Women on Antenatal Care at Nekemte Hospital, Western Ethiopia. Jundishapur J Nat Pharm Prod 2014;9:e17368.
[25] Belayneh YM, Yoseph T, Ahmed S. A Cross-Sectional Study of Herbal Medicine Use and Contributing Factors among Pregnant Women on Antenatal Care Follow-up at Dessie Referral Hospital, Northeast Ethiopia. BMC Complement Med Ther 2022;22:146.
[26] Tweheyo M, Amanya BK, Turyahabwe N. Feeding Patterns of Sitatunga (Tragelaphus speki) in the RushebeyaKanyabaha Wetland, South Western Uganda. Afr J Ecol 2010;48:1045-52.
[27] Catherine K, Mugisha KM, Bright W, Engeu OP, Kahwa I. Documentation and Phytochemical Screening of Most Commonly Used Nutri-Medicinal Plants by Pregnant Women In Kyeizooba, Bushenyi District, Western Uganda. J Pharmacogn Nat Prod 2020;6:1.
[28] Rashmi S, Bhuvneshvar K, Ujala V. Drug Utilization Pattern during Pregnancy in North India. Indian J Med Sci 2006;60:277-87.
[29] Ahirwar S, Chourasia S, Mahajan B. Drugs Used during Pregnancy and Lactation. J Pharm Sci Med 2021;6:78-103.
[30] Bauer AZ, Kriebel D, Herbert MR, Bornehag CG, Swan SH. Prenatal Paracetamol Exposure and Child Neurodevelopment: A Review. Horm Behav 2018;101:125-47.
[31] Shaheen SO, Newson RB, Sherriff A, Henderson AJ, Heron JE, Burney PG, et al. Paracetamol Use in Pregnancy and Wheezing in Early Childhood. Thorax 2002;57:958-63.
[32] Hassouna A, Allam H. Limited dose Warfarin Throughout Pregnancy in Patients with Mechanical Heart Valve Prosthesis: A Meta-Analysis. Interact Cardiovasc Thorac Surg 2014;18:797-806.
[33] Blickstein D, Blickstein I. The Risk of Fetal Loss Associated with Warfarin Anticoagulation. Int J Gynecol Obst 2002;78:221-5.
[34] Nordeng H, Lupattelli A, Romøren M, Koren G. Neonatal Outcomes after Gestational Exposure to Nitrofurantoin. Obstet Gynecol 2013;121:306-13.
[35] Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH, Vitamins in Pre-eclampsia (VIP) Trial Consortium. Vitamin C and Vitamin E in Pregnant Women at Risk for Pre-Eclampsia (VIP Trial): Randomised PlaceboControlled Trial. Lancet 2006;367:1145-54.
[36] Bruno LO, Simoes RS, de Jesus Simoes M, Girão MJ, Grundmann O. Pregnancy and Herbal Medicines: An Unnecessary Risk for Women’s Health-A Narrative Review. Phytother Res 2018;32:796-810.
[37] McLay JS, Izzati N, Pallivalapila AR, Shetty A, Pande B, Rore C, et al. Pregnancy, Prescription Medicines and the Potential Risk of Herb-Drug Interactions: A CrossSectional Survey. BMC Complement Altern Med 2017;17:543.
[38] Price HR, Collier AC. Analgesics in Pregnancy: An Update on Use, Safety and Pharmacokinetic Changes in Drug Disposition. Curr Pharm Des 2017;23:6098-114.
[39] Watts DH. Teratogenicity Risk of Antiretroviral Therapy in Pregnancy. Curr HIV/AIDS Rep 2007;4:135-40.
[40] Zaganjor I, Sekkarie A, Tsang BL, Williams J, Razzaghi H, Mulinare J, et al. Describing the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review. PLoS One 2016;11:e0151586.
[41] Pereira GF, Kim A, Jalil EM, Fonseca FF, Shepherd BE, Veloso VG, et al. Dolutegravir and Pregnancy Outcomes in Women on Antiretroviral Therapy in Brazil: ARetrospective National Cohort Study. Lancet HIV 2021;8:e33-41.
[42] Laker EA, Arinaitwe A, Owarwo N, Onzia A, Nasasira B, Wailagala A, et al. The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices Made by Women. Drug Saf 2020;43:1133-40.
[43] Rubin JD, Ferencz C, Loffredo C. Use of Prescription and non-prescription drugs in pregnancy. The BaltimoreWashington infant study group. J Clin Epidemiol 1993;46:581-9.
[44] Fukunaga R, Morof D, Blanton C, Ruiz A, Maro G, Serbanescu F. Factors Associated with Local Herb Use during Pregnancy and Labor among Women in Kigoma Region, Tanzania, 2014-2016. BMC Pregnancy Childbirth 2020;20:122.
[45] Smolina K, Hanley GE, Mintzes B, Oberlander TF, Morgan S. Trends and Determinants of Prescription Drug Use during Pregnancy and Postpartum in British Columbia, 2002-2011: A Population-Based Cohort Study. PLoS One 2015;10:e0128312.
[46] Ceulemans M, Foulon V, Panchaud A, Winterfeld U, Pomar L, Lambelet V, et al. Self-Reported Medication Use among Pregnant and Breastfeeding Women during the Covid-19 Pandemic: A Cross-Sectional Study in Five European Countries. Int J Environ Res Public Health 2022;19:1389.
[47] Trønnes JN, Lupattelli A, Nordeng H. Safety Profile of Medication Used during Pregnancy: Results of a Multinational European Study. Pharmacoepidemiol Drug Saf 2017;26:802-11.
[48] Roberson EK, Hurwitz EL. Prescription Drug Use during and Immediately before Pregnancy in Hawai ‘i-Findings from the Hawai ‘i Pregnancy Risk Assessment Monitoring System, 2009-2011. Hawaii J Med Public Health 2014;73:382-6.
[49] Yadesa TM, Kitutu FE, Tamukong R, Alele PE. Prevalence, Incidence, and Characteristics of Adverse Drug Reactions among Older Adults Hospitalized at Mbarara Regional Referral Hospital, Uganda: A Prospective Cohort Study. Clin Interv Aging 2021;16:1705-21.
[50] Mbarambara PM, Songa PB, Wansubi LM, Mututa PM, Minga BB, Bisangamo CK. Self-Medication Practice among Pregnant Women Attending Antenatal Care at Health Centers in Bukavu, Eastern DR Congo. Int J Innov Appl Stud 2016;16:38.